News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
HIV
Infectious disease
Anticipating Approval, Gilead Gears Up for Mid-Year Launch for Lenacapavir PrEP
Gilead beat consensus estimates in Q4 with $7.6 billion in revenue, driven largely by its HIV drug Biktarvy and CAR T therapies Trodelvy and Yescarta.
February 12, 2025
·
2 min read
·
Tristan Manalac
PRESS RELEASES
Press Releases
Merck Announces Positive Data from Phase 3 Trials that Show the Investigational, Once-Daily, Oral, Two-Drug Regimen of Doravirine/Islatravir (DOR/ISL) Maintained HIV-1 Viral Suppression at Week 48
March 12, 2025
·
19 min read
Press Releases
Gilead Presents New HIV Treatment and Cure Research Data at CROI 2025, Including an Investigational Long-Acting, Twice-Yearly Therapy Option
March 12, 2025
·
16 min read
Press Releases
Theratechnologies CROI Presentation Highlights Limitations of Using BMI to Assess Cardiovascular (CV) Risk in People with HIV
March 12, 2025
·
5 min read
Press Releases
First Clinical Data for Gilead’s Investigational Once-Yearly Lenacapavir for HIV Prevention Presented at CROI 2025 and Published in The Lancet
March 11, 2025
·
10 min read
Press Releases
Immunocore presents initial multiple ascending dose data for HIV functional cure candidate in an oral presentation at CROI 2025
March 11, 2025
·
9 min read
Press Releases
Gilead’s Capsid Revolution Meets Our Capsid Solutions: Sino Biological – Engineering the Tools to Outsmart HIV
March 10, 2025
·
4 min read
Press Releases
Feinstein Institutes Research Finds Hidden Genetic Clues May Explain HIV Resistance and Treatment
February 25, 2025
·
3 min read
Press Releases
European Medicines Agency Validates Gilead’s Marketing Authorization Application and EU-Medicines for All Application for Twice-Yearly Lenacapavir for HIV Prevention
February 25, 2025
·
7 min read
Press Releases
U.S. FDA Accepts Gilead’s New Drug Applications for Twice-Yearly Lenacapavir for HIV Prevention Under Priority Review
February 18, 2025
·
8 min read
Press Releases
ViiV Healthcare and the pan-Canadian Pharmaceutical Alliance (pCPA) successfully finalize negotiations for APRETUDE for HIV-1 Pre-Exposure Prophylaxis
February 14, 2025
·
5 min read
Press Releases
HOOKIPA Pharma Announces Enrollment Completion of Phase 1b Clinical Trial Evaluating HB-500 for the Treatment of HIV
January 30, 2025
·
6 min read
Press Releases
HIV Clinical Trials Market Size to Hit USD 2.19 Billion by 2031, Says Coherent Market Insights
January 16, 2025
·
1 min read
Press Releases
MedMira Receives Health Canada Approval for Its Reveal(R) G4 Rapid HIV-1/2 Test for Point-of-Care Use
January 15, 2025
·
3 min read
Press Releases
ATCC Announces Award from NCI to Support Research and Vaccine Development for Cancer and HIV
January 9, 2025
·
2 min read